Abbott

AbbottAbbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. For more information, please visit http://www.abbott.com

Abbott RSS Channel

Filters
List of articles in category Abbott
Title Published Date
Abbott and Omada Health partner to offer integrated digital health and coaching experience for people with Type 2 diabetes 15 October 2019
Abbott and Abbott Fund launch 'Future Well Kids' program to help students shape healthier lives 09 October 2019
Abbott announces new data that shows artificial intelligence technology can help doctors better determine which patients are having a heart attack 12 September 2019
Abbott to acquire Cephea Valve Technologies, Inc. 17 January 2019
Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor 08 May 2017
A great place to work, according to Science 28 October 2016
Abbott announces CE Mark for world's longest coronary drug eluting stent 21 May 2013
Abbott's HUMIRA® (Adalimumab) approved for severe active pediatric Crohn's disease 26 November 2012
Abbott announces CE Mark and European launch of next-generation XIENCE Xpedition™ 21 August 2012
Abbott again named one of the Best Workplaces in Europe 21 June 2012
Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe 15 May 2012
Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC) 11 April 2012
First-of-its-Kind Endovascular Trial of the Investigational Esprit(TM) Therapy 21 December 2011
EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets 20 December 2010
Abbott Announces European Launch of TREK(TM) Catheter System 27 May 2010
Abbott Honored as a Great Place to Work Across Europe 21 May 2010
Abbott Completes Acquisition of Solvay Pharmaceuticals 16 February 2010
Monoclonal Antibody Adds Early-Stage Biologic to Abbott's Oncology Pipeline 02 February 2010
Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes 09 November 2009
Abbott to Acquire Solvay Pharmaceuticals Business 28 September 2009